Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$177.71 +4.0%	$162.49	$111.09 ▼ $183.00	$10.86B	0.37	494,647 shs	452,056 shs
CGON CG Oncology	$25.46 -1.5%	$24.23	$14.80 ▼ $40.47	$1.94B	0.86	834,363 shs	780,709 shs
LEGN Legend Biotech	$35.84 -2.7%	$32.06	$27.34 ▼ $60.87	$6.59B	0.13	1.33 million shs	1.35 million shs
ROIV Roivant Sciences	$11.08 -2.1%	$10.85	$8.73 ▼ $13.06	$7.53B	1.16	5.58 million shs	6.06 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+4.05%	+2.63%	+12.76%	+7.93%	+39.23%
CGON CG Oncology	-1.55%	-5.70%	+0.12%	-7.35%	-26.54%
LEGN Legend Biotech	-2.69%	+3.05%	+29.01%	-5.39%	-15.57%
ROIV Roivant Sciences	-2.12%	0.00%	+2.69%	+3.45%	+3.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASND Ascendis Pharma A/S	2.5482 of 5 stars	3.5	3.0	2.1	1.7	0.6
CGON CG Oncology	2.4652 of 5 stars	4.5	1.0	2.9	0.8	0.0
LEGN Legend Biotech	2.268 of 5 stars	3.5	1.0	3.3	1.7	0.6
ROIV Roivant Sciences	2.254 of 5 stars	3.5	3.0	1.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$220.67	24.17% Upside
CGON CG Oncology	3.00	Buy	$58.22	128.68% Upside
LEGN Legend Biotech	2.91	Moderate Buy	$76.20	112.61% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	57.94% Upside

Current Analyst Ratings Breakdown

Latest CGON, LEGN, ASND, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	ASND Ascendis Pharma A/S	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$215.00 ➝ $224.00
6/9/2025	ASND Ascendis Pharma A/S	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$201.00 ➝ $216.00
6/3/2025	ASND Ascendis Pharma A/S	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$196.00 ➝ $201.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/14/2025	LEGN Legend Biotech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$88.00 ➝ $71.00
5/14/2025	LEGN Legend Biotech	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$55.00 ➝ $55.00
5/12/2025	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$200.00 ➝ $200.00
5/5/2025	ASND Ascendis Pharma A/S	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$180.00 ➝ $250.00
5/2/2025	ASND Ascendis Pharma A/S	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$205.00 ➝ $210.00
5/2/2025	ASND Ascendis Pharma A/S	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$200.00 ➝ $245.00

(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$368.70M	29.45	N/A	N/A	($1.88) per share	-94.53
CGON CG Oncology	$662K	2,931.55	N/A	N/A	($1.94) per share	-13.12
LEGN Legend Biotech	$728.30M	9.04	N/A	N/A	$6.88 per share	5.21
ROIV Roivant Sciences	$29.05M	259.26	N/A	N/A	$7.76 per share	1.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$409.12M	-$6.28	N/A	740.46	N/A	-104.54%	N/A	-39.23%	9/2/2025 (Estimated)
CGON CG Oncology	-$48.61M	-$1.51	N/A	N/A	N/A	-10,642.98%	-18.97%	-15.36%	8/14/2025 (Estimated)
LEGN Legend Biotech	-$518.25M	-$0.59	N/A	N/A	N/A	-66.92%	-29.69%	-19.45%	8/8/2025 (Estimated)
ROIV Roivant Sciences	$4.35B	-$0.25	N/A	N/A	N/A	-119.54%	-14.05%	-12.81%	8/6/2025 (Estimated)

Latest CGON, LEGN, ASND, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/13/2025	Q1 2025	LEGN Legend Biotech	-$0.40	-$0.07	+$0.33	-$0.27	$190.83 million	$195.05 million
5/1/2025	Q1 2025	ASND Ascendis Pharma A/S	-$1.56	-$1.66	-$0.10	-$1.66	$98.56 million	$123.97 million
3/25/2025	Q4 2024	CGON CG Oncology	-$0.37	-$0.48	-$0.11	-$0.48	$0.11 million	$0.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	N/A	1.17	0.84
CGON CG Oncology	N/A	35.32	35.32
LEGN Legend Biotech	0.27	4.98	4.90
ROIV Roivant Sciences	N/A	37.91	37.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
CGON CG Oncology	26.56%
LEGN Legend Biotech	70.89%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
CGON CG Oncology	7.40%
LEGN Legend Biotech	0.02%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	640	61.09 million	36.41 million	Optionable
CGON CG Oncology	61	76.23 million	N/A	Optionable
LEGN Legend Biotech	1,070	183.76 million	182.60 million	Optionable
ROIV Roivant Sciences	860	679.81 million	657.18 million	Optionable

CGON, LEGN, ASND, and ROIV Headlines

Recent News About These Companies

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16 at 7:00 AM | globenewswire.com

Roivant Sciences à la conférence Goldman Sachs : focus sur l’exécution stratégique

June 10, 2025 | fr.investing.com

Roivant Sciences Ltd. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04:00 PM

June 10, 2025 | zonebourse.com

GAMMA Investing LLC Has $6.49 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 10, 2025 | marketbeat.com

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

June 9, 2025 | globenewswire.com

Vivek Ramaswamy Sells 547,430 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

June 8, 2025 | americanbankingnews.com

Selon un récent dépôt auprès de la SEC, un initié de Roivant Sciences a vendu des actions pour une valeur de 8 454 808 dollars.

June 7, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 200,800 Shares

June 7, 2025 | insidertrades.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $2,246,952.00 in Stock

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Vivek Ramaswamy Sells 547,430 Shares

June 6, 2025 | marketbeat.com

Roivant Sciences Ltd. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 04:20 PM

June 6, 2025 | zonebourse.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

June 5, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 566,278 Shares of Stock

June 5, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

June 5, 2025 | insidertrades.com

California State Teachers Retirement System Acquires 37,982 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

June 4, 2025 | marketbeat.com

Jefferies Financial Group Inc. Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1, 2025 | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Trading 5.5% Higher - Here's Why

May 30, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPS

May 30, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript

May 30, 2025 | insidermonkey.com

What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings

May 30, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON, LEGN, ASND, and ROIV Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$177.71 +6.91 (+4.05%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$177.80 +0.09 (+0.05%)

As of 06/16/2025 07:00 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

CG Oncology NASDAQ:CGON

$25.46 -0.40 (-1.55%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$25.71 +0.25 (+1.00%)

As of 04:02 AM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Legend Biotech NASDAQ:LEGN

$35.84 -0.99 (-2.69%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$34.59 -1.25 (-3.49%)

As of 04:49 AM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Roivant Sciences NASDAQ:ROIV

$11.08 -0.24 (-2.12%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$11.00 -0.08 (-0.76%)

As of 04:35 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time